about
Nanotechnology Based Approaches for Enhancing Oral Bioavailability of Poorly Water Soluble Antihypertensive DrugsDesigning Dendrimer and Miktoarm Polymer Based Multi-Tasking Nanocarriers for Efficient Medical TherapyResveratrol and cancer: Challenges for clinical translationNovel peptide-dendrimer conjugates as drug carriers for targeting nonsmall cell lung cancer.Synthesis and preliminary evaluation in vitro of novel naproxen-dendritic peptide conjugates.Targeting the efficacy of a dendrimer-based nanotherapeutic in heterogeneous xenograft tumors in vivoPeptide and glycopeptide dendrimers and analogous dendrimeric structures and their biomedical applications.Targeted delivery of polyamidoamine-paclitaxel conjugate functionalized with anti-human epidermal growth factor receptor 2 trastuzumabDegradable polyethylenimine derivate coupled to a bifunctional peptide R13 as a new gene-delivery vectorTrastuzumab-grafted PAMAM dendrimers for the selective delivery of anticancer drugs to HER2-positive breast cancer.Design of biocompatible dendrimers for cancer diagnosis and therapy: current status and future perspectives.Dendrimers and miktoarm polymers based multivalent nanocarriers for efficient and targeted drug delivery.Docetaxel nanotechnology in anticancer therapy.Pharmacoinformatic approaches to understand complexation of dendrimeric nanoparticles with drugs.Oral bioavailability: issues and solutions via nanoformulations.The dendrimer paradox--high medical expectations but poor clinical translation.A multivalent probe for AI-2 quorum-sensing receptorsCytotoxicity and in vitro characterization studies of synthesized Jeffamine-cored PAMAM dendrimers.Targeted delivery system of nanobiomaterials in anticancer therapy: from cells to clinics.A new strategy to investigate the toxicity of nanomaterials using Langmuir monolayers as membrane models.Dendrimeric Guanidinoneomycin for Cellular Delivery of Bio-macromolecules.The effect of PAMAM dendrimer concentration, generation size and surface functional group on the aqueous solubility of candesartan cilexetil.Development of a Topical Resveratrol Formulation for Commercial Applications Using Dendrimer Nanotechnology.Optimization of carboxylate-terminated poly(amidoamine) dendrimer-mediated cisplatin formulation.
P2860
Q26745076-930E0112-2D69-4CE7-8489-4DDEFC85CE3CQ26782404-643E1980-C885-41CA-8900-BE0ED257F70AQ27015712-9D545A02-ECA9-49ED-B4AB-567C46FD49B6Q30997567-526BAD93-0794-41A7-A76E-318F0825D523Q33482970-F13E1335-E0DF-493A-8AAB-6CDA46B01286Q33640555-B9F9C68A-5263-487B-975B-EC984F1155FCQ33740696-D45618AB-BBDD-425A-BE47-6047747EC6FDQ35209810-D0F5B87A-AA3E-4B5C-A061-6C2665A987A7Q35821070-3CC24671-E5B5-46FC-B19E-0FD7F1569A6AQ36774169-41D90047-C6E8-4906-BCF9-F8D8434D8ABEQ37834336-D81E04F8-3A79-4EDA-9998-38DB0F9E55CEQ37886750-DE12AD6C-2B69-4F01-AAEF-DD8FBD5FB0CDQ38003964-ED2B389D-0208-4B6B-B860-9841D535A776Q38179927-6DA89C1F-6C06-46DD-9538-B67979182A7CQ38349734-99F3B9C0-724B-490B-B78E-3ED8383F46CEQ38478308-57EA62DA-4152-4A94-9512-E176077EAFA1Q38848395-42B47B9D-17B3-42D0-BB2A-60D0EAAF6456Q39124574-0231618A-E047-4864-AA28-E722266E7D4BQ41953738-A5DCC3AE-0A79-45C2-89E6-02FC212386EEQ45874674-0EA721E1-52DF-475C-9614-C76758660DCAQ46699693-7F7BCEE1-3514-43AC-B999-3AE522CE9CA6Q47284235-EBDD6DDC-1539-4A81-AB36-2204655608E2Q50210475-33EB3968-A406-49F0-BA4B-675EEE6BA6B5Q54594365-ADC80D51-C1EF-4074-ABA1-D7A8D175D6A5
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Dendrimers for enhanced drug solubilization.
@en
Dendrimers for enhanced drug solubilization.
@nl
type
label
Dendrimers for enhanced drug solubilization.
@en
Dendrimers for enhanced drug solubilization.
@nl
prefLabel
Dendrimers for enhanced drug solubilization.
@en
Dendrimers for enhanced drug solubilization.
@nl
P2860
P356
P1433
P1476
Dendrimers for enhanced drug solubilization
@en
P2093
Sonke Svenson
P2860
P304
P356
10.2217/17435889.3.5.679
P577
2008-10-01T00:00:00Z